Corcept Therapeutics Inc

Highly Engaged Employees

Corcept Therapeutics Inc, established in 1998, is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company focuses on addressing unmet medical needs through rigorous scientific research and clinical development, aiming to improve patient outcomes in challenging therapeutic areas. Corcept Therapeutics Inc operates within the competitive landscape of the healthcare and pharmaceuticals industry, striving to bring innovative treatments to market.

The company's commercial-stage product, Korlym tablets, is approved for treating hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who also have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Corcept Therapeutics Inc is actively advancing a robust pipeline, including relacorilant in Phase III trials for Cushing's syndrome and adrenal cancer, dazucorilant in Phase II for amyotrophic lateral sclerosis, and miricorilant in Phase IIb for nonalcoholic steatohepatitis. With a revenue of $769.1M and an employee range of 500-1,000 employees, the company maintains a significant operational footprint. Learn about Corcept Therapeutics Inc's global headquarters for detailed location information.

Corcept Therapeutics Inc competes with numerous pharmaceutical entities, including Supernus Pharmaceuticals and Collegium Pharmaceutical, among others. The company has secured significant funding throughout its history, enabling its extensive research and development efforts. For a deeper understanding of its financial standing and market performance, users can Explore financial highlights. To learn more about the individuals driving its strategic vision and operational execution, consider to Meet Corcept Therapeutics Inc's team.